OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $364.06 million. The enterprise value is $389.07 million.
Important Dates
The next confirmed earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.57 million shares outstanding. The number of shares has increased by 4.07% in one year.
| Current Share Class | 18.57M |
| Shares Outstanding | 18.57M |
| Shares Change (YoY) | +4.07% |
| Shares Change (QoQ) | +2.95% |
| Owned by Insiders (%) | 14.94% |
| Owned by Institutions (%) | 63.79% |
| Float | 14.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.18 |
| PS Ratio | 3.62 |
| Forward PS | 3.45 |
| PB Ratio | 3.20 |
| P/TBV Ratio | 76.52 |
| P/FCF Ratio | 36.42 |
| P/OCF Ratio | 36.17 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 48.87, with an EV/FCF ratio of 37.62.
| EV / Earnings | n/a |
| EV / Sales | 3.71 |
| EV / EBITDA | 48.87 |
| EV / EBIT | 107.01 |
| EV / FCF | 37.62 |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.57 |
| Quick Ratio | 2.41 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 3.53 |
| Debt / FCF | 2.80 |
| Interest Coverage | 0.61 |
Financial Efficiency
Return on equity (ROE) is -8.21% and return on invested capital (ROIC) is 1.49%.
| Return on Equity (ROE) | -8.21% |
| Return on Assets (ROA) | 1.33% |
| Return on Invested Capital (ROIC) | 1.49% |
| Return on Capital Employed (ROCE) | 2.45% |
| Revenue Per Employee | $812,000 |
| Profits Per Employee | -$76,504 |
| Employee Count | 129 |
| Asset Turnover | 0.61 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OptimizeRx has paid $565,000 in taxes.
| Income Tax | 565,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +255.25% in the last 52 weeks. The beta is 1.25, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | +255.25% |
| 50-Day Moving Average | 18.70 |
| 200-Day Moving Average | 12.22 |
| Relative Strength Index (RSI) | 50.93 |
| Average Volume (20 Days) | 253,512 |
Short Selling Information
The latest short interest is 1.72 million, so 9.24% of the outstanding shares have been sold short.
| Short Interest | 1.72M |
| Short Previous Month | 1.72M |
| Short % of Shares Out | 9.24% |
| Short % of Float | 12.01% |
| Short Ratio (days to cover) | 5.00 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $104.75 million and -$9.87 million in losses. Loss per share was -$0.54.
| Revenue | 104.75M |
| Gross Profit | 67.45M |
| Operating Income | 3.64M |
| Pretax Income | -9.30M |
| Net Income | -9.87M |
| EBITDA | 7.96M |
| EBIT | 3.64M |
| Loss Per Share | -$0.54 |
Full Income StatementBalance Sheet
The company has $16.59 million in cash and $28.98 million in debt, giving a net cash position of -$12.39 million or -$0.67 per share.
| Cash & Cash Equivalents | 16.59M |
| Total Debt | 28.98M |
| Net Cash | -12.39M |
| Net Cash Per Share | -$0.67 |
| Equity (Book Value) | 119.28M |
| Book Value Per Share | 6.43 |
| Working Capital | 33.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.41 million and capital expenditures -$72,000, giving a free cash flow of $10.34 million.
| Operating Cash Flow | 10.41M |
| Capital Expenditures | -72,000 |
| Free Cash Flow | 10.34M |
| FCF Per Share | $0.56 |
Full Cash Flow StatementMargins
Gross margin is 64.39%, with operating and profit margins of 3.47% and -9.42%.
| Gross Margin | 64.39% |
| Operating Margin | 3.47% |
| Pretax Margin | -8.88% |
| Profit Margin | -9.42% |
| EBITDA Margin | 7.60% |
| EBIT Margin | 3.47% |
| FCF Margin | 9.87% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.07% |
| Shareholder Yield | -4.07% |
| Earnings Yield | -2.62% |
| FCF Yield | 2.75% |
Analyst Forecast
The average price target for OptimizeRx is $12.19, which is -37.84% lower than the current price. The consensus rating is "Buy".
| Price Target | $12.19 |
| Price Target Difference | -37.84% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 1.96 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.96 |
| Piotroski F-Score | 6 |
